Recombinant Canine Tie-2 His-tag Protein, CF

Catalog #: 10781-T2 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
10781-T2-050

Recombinant Canine Tie-2 His-tag Protein Binding Activity

2 Images

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Canine Tie-2 His-tag Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. When Recombinant Canine Tie-2 His-tag (Catalog # 10781-T2) is immobilized at 0.5 µg/mL (100 µL/well), Recombinant Human Angiopoietin-2 (Catalog # 623-AN) binds with an ED₅₀ of 0.40-3.60 ng/mL

Source

Mouse myeloma cell line, NS0-derived canine Tie-2 protein
Ala23-Lys746, with a C-terminal 6-His tag

Accession #

XP_005626754.1

N-terminal Sequence
Analysis

Ala23

Predicted Molecular Mass

82 kDa

SDS-PAGE

95-105 kDa, under reducing conditions

Product Datasheets

10781-T2

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

10781-T2

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Binding Activity

View Larger

When Recombinant Canine Tie‑2 His-tag (Catalog # 10781-T2) is immobilized at 0.5 µg/mL (100 µL/well), Recombinant Human Angiopoietin-2 (623-AN) binds with an ED₅₀ of 0.40-3.60 ng/mL.

SDS-PAGE

View Larger

2 μg/lane of Recombinant Canine Tie-2 His-tag (Catalog # 10781-T2) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 95-105 kDa.

Reconstitution Calculator

Background: Tie-2

Tie-2, also known as Angiopoietin-1 receptor and Tek, along with the closely related Tie1, are vascular-specific receptor tyrosine kinases (RTKs) involved in angiogenesis, vascular development, and hematopoiesis (1, 2). The Tie molecules are characterized by three immunoglobulin-like domains, three epidermal growth factor (EGF)-like domains, and three fibronectin type III-like repeats in the extracellular domain (ECD) and a split tyrosine kinase domain in the cytoplasmic region (3, 4). The ECD of canine Tie-2 shares 94% amino acid sequence identity with human Tie-2. The ECD of human Tie-2 is known to be cleaved from the cell surface, releasing a ~75 kDa soluble Tie-2 (5). Tie-2 is expressed primarily on endothelial and hematopoietic progenitor cells and plays central roles in both developmental and tumor-induced angiogenesis of the adult vascular system (6). Tie receptor signaling is modulated by angiopoietins (Ang), a family secreted, multimeric growth factor ligands (2). Tie-2 signaling is activated by Ang1 and inhibited by Ang2, whereas Tie1 is considered an orphan receptor with no known ligands (7). Tie-2 and Tie1 can form heteromeric complexes in cells that express both receptors and this complex might attenuate signaling from Tie-2 (1, 8, 9). Tie-2 overexpression has been documented in breast, ovarian and hepatocellular tumors, as well as in glioblastomas and modulation of the Tie signaling pathway has been a target for the treatment of numerous diseases and cancers (10, 11).

References

Zhang, Y. et al. (2019) iScience. 20:497
Eklund, L. and Saharinen, P. (2013) Exp Cell Res 319:1271.
Seegar, T.C.M. et al. (2010). Molec Cell. 37: 643.
Barton, W.A. et al. (2006). Nat Struc & Molec Biol. 13:524.
Findley, C.M. et al. (2007) Arterioscler Thromb. Vasc. Biol. 12:2619.
Huang, H. et al. (2010) Nat. Rev. Cancer 10:575
Saharinen, P. et al. (2005) J. Cell Biol. 169:239.
Leppanen, V. et al. (2017) PNAS. 114:4376.
Song, S. et al. (2012) Biochem and Biophy Res. Comm. 419:281.
Saharinen, P. et al. (2017) Nat. Rev. Drug Discov. 16:635.
Grenga, I. et al. (2015) J. Immunotherapy Cancer 3:52.

Long Name

Tyrosine Kinase with Immunoglobulin and Epidermal Growth Factor Homology Domains 2

Entrez Gene IDs

7010 (Human); 21687 (Mouse); 89804 (Rat); 396729 (Porcine); 403714 (Canine); 102122204 (Cynomolgus Monkey); 30747 (Zebrafish)

Alternate Names

angiopoietin-1 receptor; CD202b antigen; CD202b; EC 2.7.10; EC 2.7.10.1; hTIE2; p140 TEK; soluble TIE2 variant 1; soluble TIE2 variant 2; TEK tyrosine kinase, endothelial; TEK; Tie2; Tie-2; TIE2CD202b; Tunica interna endothelial cell kinase; Tyrosine-protein kinase receptor TEK; Tyrosine-protein kinase receptor TIE-2; venous malformations, multiple cutaneous and mucosal; VMCM; VMCM1